(Q37785479)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20818326%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

title

Prostate cancer screening: current status and future perspectives (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20818326%20AND%20SRC:MED&resulttype=core&format=json

prostate cancer screening

13 February 2020

main subject

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20818326%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

author name string

Gerald L Andriole

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20818326%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

language of work or name

English

0 references

publication date

1 September 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20818326%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

published in

Nature Reviews Urology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20818326%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20818326%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20818326%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

page(s)

487-493

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20818326%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrurol.2010.120

13 February 2020

exact match

0 references

cites work

Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

21 January 2018

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer

31 March 2020

2 references

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

31 March 2020

https://pubmed.ncbi.nlm.nih.gov/20818326

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

Contemporary risk profile of prostate cancer in the United States

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

Screening with prostate specific antigen and metastatic prostate cancer risk: a population based case-control study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

Prostate Cancer Grade Assignment: The Effect of Chronological, Interpretive and Translation Bias

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

Prostate cancer and the Will Rogers phenomenon.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

Quantifying the role of PSA screening in the US prostate cancer mortality decline

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

Studies of prostate-cancer mortality: caution advised

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

The effectiveness of screening for prostate cancer: a nested case-control study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

Prostate cancer incidence and mortality in the United States and the United Kingdom

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

Comparison of trends in prostate-cancer mortality in England and Wales and the USA.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

20-year outcomes following conservative management of clinically localized prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

European Association of Urology Position Statement on Screening for Prostate Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

Japanese Urological Association guidelines on prostate-specific antigen-based screening for prostate cancer and the ongoing cluster cohort study in Japan

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

Screening for prostate cancer in U.S. men ACPM position statement on preventive practice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

Mortality results from a randomized prostate-cancer screening trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

Screening and prostate-cancer mortality in a randomized European study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

Efficacy vs effectiveness in prostate-specific antigen screening

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-Rotterdam.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

The influence of finasteride on the development of prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

Effect of Finasteride on the Sensitivity of PSA for Detecting Prostate Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

Effect of dutasteride on the risk of prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

Urine biomarkers in prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

Rational approach to implementation of prostate cancer antigen 3 into clinical care

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

Cumulative association of five genetic variants with prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

Complexities of prostate-cancer risk

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.120

The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20818326

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The effect of study arm on prostate cancer treatment in the large screening trial ERSPC.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20818326

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRUROL.2010.120

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20818326%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference